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Low-dose methotrexate is an effective and safe
management for extensive and severe psoriasis. It
may cause adverse reactions ranging from trivial to
life threatening. Among them, hepatotoxicity and
pancytopenia are the common serious side effects,
whereas painful ulceration of psoriatic plaques as an
early cutaneous manifestation of low-dose metho-
trexate toxicity has rarely been reported.1-5 Here, we
describe a case of psoriatic plaque ulceration
induced by low-dose methotrexate and highlight
the risk factors and possible mechanisms of toxicity.
CASE REPORT
A 34-year-old Taiwanesemanwas admitted to our
inpatient ward for erythrodermic psoriasis. Although
he had 14-year history of plaque psoriasis, he was
never prescribed systemic medications except for
etoricoxib and leflunomide, which had been used
for psoriatic arthritis for 2 years and were discon-
tinued because of abnormal liver function. In addi-
tion, amlodipine/benazepril and bisoprolol were
taken for 4 years to control hypertension. After
admission, celecoxib, 400 mg daily, was prescribed
for joint pain along with the continuous use of
amlodipine/benazepril and bisoprolol. Narrow-
band ultraviolet B, topical corticosteroids and
vitamin D3 analog were used initially, but the skin
lesions responded little. Systemic treatment with
low-dose methotrexate (15 mg/wk) and folate sup-
plementation (5 mg daily) was started. Multiple
painful ulcerations on his psoriatic plaques devel-
oped 1 week later. The patient was afebrile with
normal vital signs. Dermatologic examination foundthe Department of Dermatology, Taipei Veterans General
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ail: docs1.tw@yahoo.com.tw.several ulcerated erythematous plaques of different
sizes on the trunk and limbs, with the groin and
thighs being the most severely affected, showing a
confluence of marked, bright red, moist erosions and
ulcerations (Fig 1). The face, hands, feet, genitalia,
and mucous membranes were spared.
Complete blood count and albumin level as well
as renal and liver functions were all within the
normal range. A skin biopsy section taken from the
right flank area showed ulcers with fibrosis in the
papillary dermis along with perivascular infiltration
of lymphohistiocytes, neutrophils, and a few eo-
sinophils (Fig 2). According to the clinical and
histopathologic findings, the diagnosis of metho-
trexate toxicity was made, and the drug was,
therefore, discontinued. Symptoms and signs soon
resolved within 2 weeks after withdrawal of
methotrexate.
DISCUSSION
Methotrexate, an analog of folate that competi-
tively and irreversibly inhibits dihydrofolate reduc-
tase, is eliminated primarily by the kidneys, with 60%
to 95% excreted unchanged. Therefore, the potential
factors in the development of toxicity might include
folate deficiency, drugs that impair folate absorption
(eg, barbiturates, nitrofurantoin), drugs that inhibit
dihydrofolate reductase (eg, trimethoprim-
sulfamethoxazole, ethanol) or decrease glomerular
filtration (eg, nonsteroidal anti-inflammatory drugs),
or drugs that lower tubular secretion (eg, aspirin,
penicillin, sulfonamides, colchicine). Also, approxi-
mately 50% of methotrexate within the blood is
protein bound. Low serum albumin and medicationsJAAD Case Reports 2015;1:264-6.
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Fig 1. Clinical pictures of ulcerated psoriatic plaques. A, Erythematous psoriatic plaque with
ulcerated surface on thighs. B, Ulceration of psoriatic plaques on the right flank.
Fig 2. Histopathologic features of methotrexate-induced ulcerations. A, Skin biopsy section
adjacent to an ulcerated lesion shows focal epidermal-dermal separation and ectatic vessels. B,
Magnification shows an acanthotic epidermis with scattered dyskeratotic keratinocytes,
overlying parakeratosis, and a superficial perivascular mixed inflammatory infiltrate. (Hema-
toxylin-eosin stain; A, low power; B, high power.)
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phenytoin, tetracycline, sulfonamides, barbiturates,
probenecid, salicylates, chloramphenicol, sulfonyl-
ureas) are likely to induce methotrexate toxicity.
Other risk factors include alteration in dose (initia-
tion, re-initiation, escalation in dose), advanced age,
infections, diabetes mellitus,6 and psoriatic flares.4
The exact incidence of methotrexate-induced
ulcerated psoriatic plaques is unclear because of its
rarity. A case of methotrexate-induced ulceration in
patients without history of psoriasis has also been
reported.7 As reported by Jariwala et al,3 the skin
ulceration might develop at the onset of treatment or
during longstanding treatment as a presenting
feature of methotrexate overdose. It has also been
described as a herald for impending pancytopenia in
methotrexate toxicity.1,2,4,5
Surprisingly, most cases of methotrexate-induced
ulceration were reported in patients treated with
low-dose (7.5-25 mg/wk) instead of high-dose meth-
otrexate (100-250 mg/m2/wk), possibly because
hyperproliferative psoriatic plaques are more suscep-
tible to the effect of folate antagonism.5 Unfor-
tunately, painful, ulcerated, erythematous psoriatic
plaques can sometimes be mistaken as anexacerbation of the psoriasis, which leads to erro-
neous increase in methotrexate dosage. Kivity et al8
found that serum methotrexate concentrations, un-
detectable within 24 hours after administration, do
not reflect or correlate with clinical toxicity, as
prolonged low-dose methotrexate toxicity might be
chiefly mediated by the intracellular polyglutamate
derivatives, which cannot be measured. It is thus
unnecessary to monitor routine methotrexate serum
concentration, as there is currently no specific labo-
ratory test effective enough to confirm the diagnosis,
which ismainly based on clinical findings. Even a skin
biopsy is rarely required. Histopathologic features
include focal dermal-epidermal separation with dys-
keratotic keratinocytes and a maturation defect
related to a direct toxic antimetabolite effect on the
epidermis. Other reported features are epidermal
acanthosis, spongiosis, and focal parakeratosis in
addition to a mild, superficial perivascular and
interstitial mixed inflammatory infiltrate consisting of
lymphocytes, histiocytes, neutrophils, and eosino-
phils with ectatic vessels within the dermis.4
Nonspecific ulceration may also be present.9
Treatment of choice for bone marrow suppression
resulting from methotrexate toxicity is leucovorin
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intravenously or intramuscularly at a dose equivalent
to or higher than the lastmethotrexate dose as soon as
possible after exposure to methotrexate and every 6
hours until a significant clinical improvement is
observed.4,6 Nevertheless, treatment is usually sup-
portive because the lesions may heal rapidly with
complete re-epithelialization just a few days after
discontinuation of methotrexate.
This case suggested 3 possible causes for the
painful ulceration of psoriatic plaques including (1)
administration of methotrexate for the first time, (2)
psoriatic flare, and (3) increased methotrexate
toxicity with the combined use of methotrexate
and nonsteroidal anti-inflammatory drugs for joint
pain. Although the laboratory parameters were all
within normal limits, unexpected painful superficial
ulceration and histopathologic results suggested
methotrexate toxicity.
Increased erythema and ulceration of psoriatic
plaques in the presence of normal laboratory profile
should not always be considered an exacerbation of
disease itself, as it could be an indicator of metho-
trexate toxicity. The awareness of the sequelae in
methotrexate-induced skin ulceration is also impor-
tant to prevent fatal bone marrow suppression by
discontinuing the use of methotrexate in time.
Proper monitoring and regular review of theconcomitant medications are mandatory during
methotrexate treatment.
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